search
Back to results

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) (KARDIA-1)

Primary Purpose

Hypertension

Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Placebo
ALN-AGT01
Sponsored by
Alnylam Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring High blood pressure, Hypertension, Hypertensive, siRNA, Angiotensinogen, AGT

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive medication

Exclusion Criteria:

  • Secondary hypertension, orthostatic hypotension
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2× upper limit of normal (ULN)
  • Elevated potassium >5 mEq/L
  • Estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73m^2
  • Received an investigational agent within the last 30 days
  • Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, newly diagnosed Type 2 diabetes mellitus
  • History of any cardiovascular event within 6 months prior to randomization
  • History of intolerance to SC injection(s)

Sites / Locations

  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site
  • Clinical Trial Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

ALN-AGT01 Dose Regimen 1

ALN-AGT01 Dose Regimen 2

ALN-AGT01 Dose Regimen 3

ALN-AGT01 Dose Regimen 4

Placebo + ALN-AGT01

Arm Description

Multiple doses of ALN-AGT01 administered by subcutaneous (SC) injection during the 12-month DB treatment period.

Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.

Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.

Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.

Multiple doses of placebo administered by SC injection during the first 6 months of 12-month DB treatment period, followed by multiple doses of ALN-AGT01 administered by SC injection during the last 6 months of the 12-month DB treatment period.

Outcomes

Primary Outcome Measures

Change from Baseline at Month 3 in 24-hour Mean Systolic Blood Pressure (SBP) Assessed by Ambulatory Blood Pressure Monitoring (ABPM)

Secondary Outcome Measures

Change from Baseline at Month 3 in Office SBP
Change from Baseline at Month 6 in 24-hour Mean SBP Assessed by ABPM
Change from Baseline at Month 6 in Office SBP
Proportion of Patients with 24-hour Mean SBP Assessed by ABPM <130 mmHg and/or Reduction ≥20 mmHg without Additional Antihypertensive Medications at Month 6
Time-adjusted Change from Baseline in 24-hour Mean SBP and Diastolic Blood Pressure (DBP), Assessed by ABPM
Change from Baseline in 24-hour mean DBP, Assessed by ABPM
Change from Baseline in Office SBP and DBP
Change in Serum Angiotensinogen (AGT)
Change from Baseline in Daytime and Nighttime SBP and DBP by ABPM (Including Dipping Pattern)

Full Information

First Posted
June 14, 2021
Last Updated
October 24, 2023
Sponsor
Alnylam Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT04936035
Brief Title
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)
Acronym
KARDIA-1
Official Title
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 7, 2021 (Actual)
Primary Completion Date
April 4, 2023 (Actual)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alnylam Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
Detailed Description
Participants will receive ALN-AGT01 or placebo for the first 6 months of the 12-month double-blind (DB) treatment period. Participants randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial ALN-AGT01 regimens until the end of the 12-month DB treatment period. Participants randomized to ALN-AGT01 regimens will remain on their originally assigned regimens through remainder of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
High blood pressure, Hypertension, Hypertensive, siRNA, Angiotensinogen, AGT

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
394 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ALN-AGT01 Dose Regimen 1
Arm Type
Experimental
Arm Description
Multiple doses of ALN-AGT01 administered by subcutaneous (SC) injection during the 12-month DB treatment period.
Arm Title
ALN-AGT01 Dose Regimen 2
Arm Type
Experimental
Arm Description
Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
Arm Title
ALN-AGT01 Dose Regimen 3
Arm Type
Experimental
Arm Description
Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
Arm Title
ALN-AGT01 Dose Regimen 4
Arm Type
Experimental
Arm Description
Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
Arm Title
Placebo + ALN-AGT01
Arm Type
Placebo Comparator
Arm Description
Multiple doses of placebo administered by SC injection during the first 6 months of 12-month DB treatment period, followed by multiple doses of ALN-AGT01 administered by SC injection during the last 6 months of the 12-month DB treatment period.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo administered by SC injection
Intervention Type
Drug
Intervention Name(s)
ALN-AGT01
Intervention Description
ALN-AGT01 administered by SC injection
Primary Outcome Measure Information:
Title
Change from Baseline at Month 3 in 24-hour Mean Systolic Blood Pressure (SBP) Assessed by Ambulatory Blood Pressure Monitoring (ABPM)
Time Frame
Baseline and Month 3
Secondary Outcome Measure Information:
Title
Change from Baseline at Month 3 in Office SBP
Time Frame
Baseline and Month 3
Title
Change from Baseline at Month 6 in 24-hour Mean SBP Assessed by ABPM
Time Frame
Baseline through Month 6
Title
Change from Baseline at Month 6 in Office SBP
Time Frame
Baseline through Month 6
Title
Proportion of Patients with 24-hour Mean SBP Assessed by ABPM <130 mmHg and/or Reduction ≥20 mmHg without Additional Antihypertensive Medications at Month 6
Time Frame
Baseline through Month 6
Title
Time-adjusted Change from Baseline in 24-hour Mean SBP and Diastolic Blood Pressure (DBP), Assessed by ABPM
Time Frame
Baseline through Month 6
Title
Change from Baseline in 24-hour mean DBP, Assessed by ABPM
Time Frame
Baseline through Month 6
Title
Change from Baseline in Office SBP and DBP
Time Frame
Baseline through Month 6
Title
Change in Serum Angiotensinogen (AGT)
Time Frame
Baseline through Month 6
Title
Change from Baseline in Daytime and Nighttime SBP and DBP by ABPM (Including Dipping Pattern)
Time Frame
Baseline through Month 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive medication Exclusion Criteria: Secondary hypertension, orthostatic hypotension Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2× upper limit of normal (ULN) Elevated potassium >5 mEq/L Estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73m^2 Received an investigational agent within the last 30 days Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, newly diagnosed Type 2 diabetes mellitus History of any cardiovascular event within 6 months prior to randomization History of intolerance to SC injection(s)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Alnylam Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Clinical Trial Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
Facility Name
Clinical Trial Site
City
Tempe
State/Province
Arizona
ZIP/Postal Code
85281
Country
United States
Facility Name
Clinical Trial Site
City
Tempe
State/Province
Arizona
ZIP/Postal Code
85282
Country
United States
Facility Name
Clinical Trial Site
City
Tempe
State/Province
Arizona
ZIP/Postal Code
85283
Country
United States
Facility Name
Clinical Trial Site
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90211
Country
United States
Facility Name
Clinical Trial Site
City
La Mesa
State/Province
California
ZIP/Postal Code
91942
Country
United States
Facility Name
Clinical Trial Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Clinical Trial Site
City
Mission Hills
State/Province
California
ZIP/Postal Code
91345
Country
United States
Facility Name
Clinical Trial Site
City
Oxnard
State/Province
California
ZIP/Postal Code
93030
Country
United States
Facility Name
Clinical Trial Site
City
S. Gate
State/Province
California
ZIP/Postal Code
90280
Country
United States
Facility Name
Clinical Trial Site
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Facility Name
Clinical Trial Site
City
Vista
State/Province
California
ZIP/Postal Code
92083
Country
United States
Facility Name
Clinical Trial Site
City
Woodland Hills
State/Province
California
ZIP/Postal Code
91364
Country
United States
Facility Name
Clinical Trial Site
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20011
Country
United States
Facility Name
Clinical Trial Site
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33756
Country
United States
Facility Name
Clinical Trial Site
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States
Facility Name
Clinical Trial Site
City
Fleming Island
State/Province
Florida
ZIP/Postal Code
32003
Country
United States
Facility Name
Clinical Trial Site
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Facility Name
Clinical Trial Site
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Facility Name
Clinical Trial Site
City
Inverness
State/Province
Florida
ZIP/Postal Code
34452
Country
United States
Facility Name
Clinical Trial Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32204
Country
United States
Facility Name
Clinical Trial Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Facility Name
Clinical Trial Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32256
Country
United States
Facility Name
Clinical Trial Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33126
Country
United States
Facility Name
Clinical Trial Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33135
Country
United States
Facility Name
Clinical Trial Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33186
Country
United States
Facility Name
Clinical Trial Site
City
Naples
State/Province
Florida
ZIP/Postal Code
34102
Country
United States
Facility Name
Clinical Trial Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32801
Country
United States
Facility Name
Clinical Trial Site
City
Acworth
State/Province
Georgia
ZIP/Postal Code
30101
Country
United States
Facility Name
Clinical Trial Site
City
Columbus
State/Province
Georgia
ZIP/Postal Code
31904
Country
United States
Facility Name
Clinical Trial Site
City
Fayetteville
State/Province
Georgia
ZIP/Postal Code
30214
Country
United States
Facility Name
Clinical Trial Site
City
Macon
State/Province
Georgia
ZIP/Postal Code
31210
Country
United States
Facility Name
Clinical Trial Site
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31406
Country
United States
Facility Name
Clinical Trial Site
City
Champaign
State/Province
Illinois
ZIP/Postal Code
61822
Country
United States
Facility Name
Clinical Trial Site
City
Quincy
State/Province
Illinois
ZIP/Postal Code
62301
Country
United States
Facility Name
Clinical Trial Site
City
River Forest
State/Province
Illinois
ZIP/Postal Code
60305
Country
United States
Facility Name
Clinical Trial Site
City
Franklin
State/Province
Indiana
ZIP/Postal Code
46131
Country
United States
Facility Name
Clinical Trial Site
City
Greenfield
State/Province
Indiana
ZIP/Postal Code
46140
Country
United States
Facility Name
Clinical Trial Site
City
Valparaiso
State/Province
Indiana
ZIP/Postal Code
46383
Country
United States
Facility Name
Clinical Trial Site
City
West Des Moines
State/Province
Iowa
ZIP/Postal Code
50266
Country
United States
Facility Name
Clinical Trial Site
City
Lake Charles
State/Province
Louisiana
ZIP/Postal Code
70601
Country
United States
Facility Name
Clinical Trial Site
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70124
Country
United States
Facility Name
Clinical Trial Site
City
Prairieville
State/Province
Louisiana
ZIP/Postal Code
70769
Country
United States
Facility Name
Clinical Trial Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21229
Country
United States
Facility Name
Clinical Trial Site
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39209
Country
United States
Facility Name
Clinical Trial Site
City
Jefferson City
State/Province
Missouri
ZIP/Postal Code
65109
Country
United States
Facility Name
Clinical Trial Site
City
Henderson
State/Province
Nevada
ZIP/Postal Code
89052
Country
United States
Facility Name
Clinical Trial Site
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89119
Country
United States
Facility Name
Clinical Trial Site
City
Berlin
State/Province
New Jersey
ZIP/Postal Code
08009
Country
United States
Facility Name
Clinical Trial Site
City
Bronx
State/Province
New York
ZIP/Postal Code
10456
Country
United States
Facility Name
Clinical Trial Site
City
New York
State/Province
New York
ZIP/Postal Code
10036
Country
United States
Facility Name
Clinical Trial Site
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27408
Country
United States
Facility Name
Clinical Trial Site
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27410
Country
United States
Facility Name
Clinical Trial Site
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74135
Country
United States
Facility Name
Clinical Trial Site
City
Medford
State/Province
Oregon
ZIP/Postal Code
97504
Country
United States
Facility Name
Clinical Trial Site
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29607
Country
United States
Facility Name
Clinical Trial Site
City
Rock Hill
State/Province
South Carolina
ZIP/Postal Code
29732
Country
United States
Facility Name
Clinical Trial Site
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38119
Country
United States
Facility Name
Clinical Trial Site
City
Carrollton
State/Province
Texas
ZIP/Postal Code
75010
Country
United States
Facility Name
Clinical Trial Site
City
Cedar Park
State/Province
Texas
ZIP/Postal Code
78613
Country
United States
Facility Name
Clinical Trial Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75251
Country
United States
Facility Name
Clinical Trial Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77074
Country
United States
Facility Name
Clinical Trial Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77081
Country
United States
Facility Name
Clinical Trial Site
City
Magnolia
State/Province
Texas
ZIP/Postal Code
77355
Country
United States
Facility Name
Clinical Trial Site
City
Pearland
State/Province
Texas
ZIP/Postal Code
77584
Country
United States
Facility Name
Clinical Trial Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Clinical Trial Site
City
Stephenville
State/Province
Texas
ZIP/Postal Code
76401
Country
United States
Facility Name
Clinical Trial Site
City
Tomball
State/Province
Texas
ZIP/Postal Code
77375
Country
United States
Facility Name
Clinical Trial Site
City
Waco
State/Province
Texas
ZIP/Postal Code
76708
Country
United States
Facility Name
Clinical Trial Site
City
Holladay
State/Province
Utah
ZIP/Postal Code
84117
Country
United States
Facility Name
Clinical Trial Site
City
Appomattox
State/Province
Virginia
ZIP/Postal Code
24522
Country
United States
Facility Name
Clinical Trial Site
City
Burke
State/Province
Virginia
ZIP/Postal Code
22015
Country
United States
Facility Name
Clinical Trial Site
City
Red Deer
State/Province
Alberta
Country
Canada
Facility Name
Clinical Trial Site
City
New Minas
State/Province
Nova Scotia
Country
Canada
Facility Name
Clinical Trial Site
City
Brampton
State/Province
Ontario
Country
Canada
Facility Name
Clinical Trial Site
City
London
State/Province
Ontario
Country
Canada
Facility Name
Clinical Trial Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
Clinical Trial Site
City
Chicoutimi
State/Province
Quebec
Country
Canada
Facility Name
Clinical Trial Site
City
Mirabel
State/Province
Quebec
Country
Canada
Facility Name
Clinical Trial Site
City
Montréal
State/Province
Quebec
Country
Canada
Facility Name
Clinical Trial Site
City
Quebec City
State/Province
Quebec
Country
Canada
Facility Name
Clinical Trial Site
City
Trois-Rivières
State/Province
Quebec
Country
Canada
Facility Name
Clinical Trial Site
City
Victoriaville
State/Province
Quebec
Country
Canada
Facility Name
Clinical Trial Site
City
Bayamon
ZIP/Postal Code
00961
Country
Puerto Rico
Facility Name
Clinical Trial Site
City
Cidra
ZIP/Postal Code
00739
Country
Puerto Rico
Facility Name
Clinical Trial Site
City
Ponce
ZIP/Postal Code
00716
Country
Puerto Rico
Facility Name
Clinical Trial Site
City
San Juan
Country
Puerto Rico
Facility Name
Clinical Trial Site
City
Ivano-Frankivs'k
Country
Ukraine
Facility Name
Clinical Trial Site
City
Kharkiv
ZIP/Postal Code
61039
Country
Ukraine
Facility Name
Clinical Trial Site
City
Kharkiv
ZIP/Postal Code
61107
Country
Ukraine
Facility Name
Clinical Trial Site
City
Kharkiv
ZIP/Postal Code
61176
Country
Ukraine
Facility Name
Clinical Trial Site
City
Kharkiv
Country
Ukraine
Facility Name
Clinical Trial Site
City
Kyiv
ZIP/Postal Code
02091
Country
Ukraine
Facility Name
Clinical Trial Site
City
Kyiv
ZIP/Postal Code
03680
Country
Ukraine
Facility Name
Clinical Trial Site
City
Kyiv
ZIP/Postal Code
04053
Country
Ukraine
Facility Name
Clinical Trial Site
City
Kyiv
Country
Ukraine
Facility Name
Clinical Trial Site
City
Lviv
Country
Ukraine
Facility Name
Clinical Trial Site
City
Odesa
Country
Ukraine
Facility Name
Clinical Trial Site
City
Vinnytsia
Country
Ukraine
Facility Name
Clinical Trial Site
City
Úzhgorod
Country
Ukraine
Facility Name
Clinical Trial Site
City
Chorley
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Glasgow
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Hexham
Country
United Kingdom
Facility Name
Clinical Trial Site
City
London
Country
United Kingdom
Facility Name
Clinical Trial Site
City
Manchester
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)

We'll reach out to this number within 24 hrs